As the U.S. market rebounds from recent declines, driven by geopolitical tensions and fluctuating oil prices, major indices like the Dow Jones and Nasdaq have shown resilience with notable gains. In this dynamic environment, identifying high growth tech stocks involves looking for companies that can capitalize on technological advancements and maintain robust performance despite external pressures such as international conflicts or economic uncertainties.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Super Micro Computer | 26.38% | 39.09% | ★★★★★★ |
| Mereo BioPharma Group | 53.63% | 66.57% | ★★★★★★ |
| Ardelyx | 20.78% | 59.46% | ★★★★★★ |
| Legend Biotech | 26.68% | 57.96% | ★★★★★★ |
| TG Therapeutics | 26.46% | 38.75% | ★★★★★★ |
| AVITA Medical | 27.36% | 60.93% | ★★★★★★ |
| Alnylam Pharmaceuticals | 23.63% | 60.71% | ★★★★★★ |
| Alkami Technology | 20.54% | 76.67% | ★★★★★★ |
| Ascendis Pharma | 35.07% | 59.92% | ★★★★★★ |
| Lumentum Holdings | 22.99% | 103.97% | ★★★★★★ |
Click here to see the full list of 233 stocks from our US High Growth Tech and AI Stocks screener.
Let's review some notable picks from our screened stocks.
Mereo BioPharma Group (MREO)
Simply Wall St Growth Rating: ★★★★★★
Overview: Mereo BioPharma Group plc is a biopharmaceutical company focused on developing and commercializing therapeutics for oncology and rare diseases across the United Kingdom, the United States, and internationally, with a market cap of $438.84 million.
Operations: The company specializes in the development and commercialization of therapeutics targeting oncology and rare diseases. It operates across multiple regions, including the UK and the US, with a focus on innovative medical solutions.
Despite Mereo BioPharma Group's current unprofitability, its projected revenue growth at 53.6% annually surpasses the US market average of 8.7%, indicating a robust upward trajectory. The company is also expected to become profitable within three years, with earnings forecasted to grow by 66.57% per year, showcasing potential for significant financial improvement. Notably, its R&D investments are strategically aligned with this growth, emphasizing innovation in biotech which could lead to breakthroughs and a strong competitive position in the industry. Recent presentations at key conferences and earnings reports reflect active engagement with the broader medical community and investors, despite a net loss widening in the past year from USD 29.47 million to USD 43.25 million, signaling ongoing challenges yet a clear focus on long-term goals.
- Click here to discover the nuances of Mereo BioPharma Group with our detailed analytical health report.
Gain insights into Mereo BioPharma Group's past trends and performance with our Past report.
Anavex Life Sciences (AVXL)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company focused on developing therapeutics for central nervous system diseases in the United States, with a market cap of $685.54 million.
Operations: Anavex Life Sciences focuses on developing therapeutics for central nervous system diseases. As a clinical stage biopharmaceutical company, it does not currently generate revenue from product sales.
Anavex Life Sciences, amid a challenging financial landscape with a net loss widening to $11.2 million in Q2 2025 from $10.55 million the previous year, continues to focus on groundbreaking research and development (R&D). The company's commitment is evident as it actively engages in high-profile conferences and advances clinical trials, such as the Phase 2 study for schizophrenia treatment ANAVEX3-71. This strategic emphasis on innovation is crucial for Anavex, especially when considering its projected revenue growth of 57.2% annually and an anticipated shift to profitability within three years due to its robust pipeline of developmental drugs which could potentially transform treatment paradigms in neurological disorders.
- Take a closer look at Anavex Life Sciences' potential here in our health report.
Assess Anavex Life Sciences' past performance with our detailed historical performance reports.
Precigen (PGEN)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company focused on developing gene and cell therapies for diseases in immuno-oncology, autoimmune disorders, and infectious diseases, with a market cap of $448.67 million.
Operations: The company leverages precision technology to develop gene and cell therapies targeting immuno-oncology, autoimmune disorders, and infectious diseases.
Despite a challenging backdrop with its net loss widening to $54.15 million in Q1 2025 from $23.74 million the previous year, Precigen continues to invest heavily in innovation, evident from its participation in high-profile industry conferences like the ASGCT Annual Meeting. This strategic focus on R&D is underscored by a robust annual revenue growth projection of 50.3% and an anticipated shift to profitability within three years, supported by an aggressive expansion of its authorized shares to fuel further development. This approach may position Precigen well as it navigates through its current financial complexities towards potential future profitability.
- Dive into the specifics of Precigen here with our thorough health report.
Understand Precigen's track record by examining our Past report.
Seize The Opportunity
- Click through to start exploring the rest of the 230 US High Growth Tech and AI Stocks now.
- Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
- Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.
Curious About Other Options?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Anavex Life Sciences might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com